Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Veracyte (VCYT)
NASDAQ:VCYT
Holding VCYT?
Track your performance easily
VCYT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$18.61 - $30.52
Previous Close$22.59
Volume766.68K
Average Volume (3M)753.07K
Market Cap
$1.74B
Enterprise Value$1.52B
Total Cash (Recent Filing)$216.45M
Total Debt (Recent Filing)$12.63M
Price to Earnings (P/E)―
Beta2.00
Next Earnings
Jul 30, 2024EPS Estimate
-$0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.93
Shares Outstanding76,448,070
10 Day Avg. Volume951,304
30 Day Avg. Volume753,072
Standard Deviation0.16
R-Squared0.31
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)1.65
Price to Sales (P/S)17.55
Price to Cash Flow (P/CF)27.70
P/FCF Ratio33.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.22
Enterprise Value/Gross Profit6.14
Enterprise Value/Ebitda-54.11
Forecast
1Y Price Target
$31.50Price Target Upside39.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Veracyte News
PremiumCompany Announcements
Veracyte Inc. Reports Strong Q3 2024 GrowthBulls Say, Bears Say
Bulls Say
EarningsVCYT delivered 1Q24 revenue of $96.8M, beating expectations.
Financial PerformanceVCYT raised its 2024 guidance by $8M to $402M-410M.
Product PerformanceVolumes grew ~30% yoy for Decipher and ASP gains drove a total revenue growth rate of 36% yoy for Decipher.
Bears Say
Financial PerformanceNon-GAAP gross margin was down 70 bps Y/Y.
Product RevenueProduct revenue (Prosigna) declined 9%, driven by continued efforts to move supplier.
Revenue GrowthRevenue growth slowed to 17.5% Y/Y in 1Q24 from 22.3% in 4Q23 as strong Testing growth was partially offset by declines in both Biopharma and Other revenue and Product revenue.
---
Ownership Overview
21.73% Insiders
32.61% Mutual Funds
28.82% Other Institutional Investors
16.83% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VCYT FAQ
What was Veracyte’s price range in the past 12 months?
Veracyte lowest stock price was $18.61 and its highest was $30.52 in the past 12 months.
What is Veracyte’s market cap?
Currently, no data Available
When is Veracyte’s upcoming earnings report date?
Veracyte’s upcoming earnings report date is Jul 30, 2024 which is 145 days ago.
How were Veracyte’s earnings last quarter?
Veracyte released its earnings results on May 07, 2024. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.159 by $0.139.
Is Veracyte overvalued?
According to Wall Street analysts Veracyte’s price is currently Undervalued.
Does Veracyte pay dividends?
Veracyte does not currently pay dividends.
What is Veracyte’s EPS estimate?
Veracyte’s EPS estimate is -$0.02.
How many shares outstanding does Veracyte have?
Veracyte has 76,448,070 shares outstanding.
What happened to Veracyte’s price movement after its last earnings report?
Veracyte reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.159. Following the earnings report the stock price went down -4.327%.
Which hedge fund is a major shareholder of Veracyte?
Among the largest hedge funds holding Veracyte’s share is ARK Investment Management LLC. It holds Veracyte’s shares valued at 156M.
---
Veracyte Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$31.50 (39.44% Upside)
$31.50 (39.44% Upside)
Blogger Sentiment
Bullish
VCYT Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 726.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.9%
Last 30 Days ▲ 20.8%
Last 30 Days ▲ 20.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.61%
12-Months-Change
Fundamentals
Return on Equity
-6.20%
Trailing 12-Months
Asset Growth
3.71%
Trailing 12-Months
Company Description
Veracyte
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
---
VCYT Company Deck
---
VCYT Earnings Call
Q1 2024
0:00 / 0:00
---
VCYT Stock 12 Month Forecast
Average Price Target
$31.50
▲(39.44% Upside)
Technical Analysis
Best Analysts Covering VCYT
1 Year
1 Year Success Rate
11/18 ratings generated profit
1 Year Average Return
+44.12%
reiterated a buy rating 8 months ago
Copying Sung Ji Nam's trades and holding each position for 1 Year would result in 61.11% of your transactions generating a profit, with an average return of +44.12% per trade.
---